A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 16, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AFJK SEC filings page.
This page shows Aimei Health Technology Co., Ltd (AFJK) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The reported business has positive net income, but negative operating cash flow and liabilities exceeding assets define its financial structure.
FY2025 reported net income of$1.06M alongside operating cash flow of-$565K , so accounting earnings did not translate into cash. Operating income remained a loss of$836K even as return on assets improved to8.8% , indicating that reported net income is not reflecting core operating profitability.
FY2025 liabilities were
Current assets fell
Financial Health Signals
We do not publish a peer-relative financial health score for Aimei Health Technology Co., Ltd, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Aimei Health Technology Co., Ltd passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Key Financial Metrics
Earnings & Revenue
Aimei Health Technology Co., Ltd reported a net loss of $31K in Q3 2026. This represents a decrease of 108.8% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Cash & Balance Sheet
Aimei Health Technology Co., Ltd held $3K in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
None of these metrics is reported for Q3 2026.
Capital Allocation
None of these metrics is reported for Q3 2026.
AFJK Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Income | -$145Kn/m | -$192Kn/m | -$62Kn/m | -$251Kn/m | -$130Kn/m | -$42Kn/m | -$413Kn/m | -$402K |
| Income Tax | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 |
| Net Income | -$31K-108.8% | -$83K-119.6% | $45K-75.4% | $98K-77.9% | $352K-52.7% | $425K-30.2% | $185K-75.6% | $444K |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, EBITDA, Interest Expense, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
AFJK Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'25Filing | Q1'25Filing | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $12.8M-71.9% | $12.5M-71.9% | $12.3M-71.8% | $12.1M-83.6% | $45.5M-37.5% | $44.6M-38.0% | $43.6M-38.8% | $73.8M+4.7% |
| Current Assets | $51K+106.0% | $44K-1.5% | $19K+133.2% | $3K-90.4% | $25K-79.9% | $45K-78.2% | $8K-98.3% | $30K-94.8% |
| Cash & Equivalents | $3K+13.2% | $1K-31.4% | $19K+152.1% | $3K-89.6% | $3K-97.1% | $2K-98.6% | $7K-98.2% | $28K-95.1% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $17.6M-64.1% | $17.0M-64.1% | $16.5M-64.1% | $16.2M-78.5% | $48.9M-33.5% | $47.4M-34.6% | $46.0M-35.8% | $75.3M+6.6% |
| Current Liabilities | $4.1M+48.8% | $3.8M+73.4% | $3.5M+108.7% | $3.4M+312.7% | $2.8M+1102.1% | $2.2M+1890.7% | $1.7M+2048.2% | $817K+3188.9% |
| Non-Current Liabilities | $13.4M-70.9% | $13.2M-70.8% | $13.0M-70.7% | $12.8M-82.8% | $46.1M-37.1% | $45.2M-37.6% | $44.3M-38.1% | $74.5M+5.5% |
| Total Equity | -$4.8Mn/m | -$4.5Mn/m | -$4.2Mn/m | -$4.1Mn/m | -$3.4Mn/m | -$2.9Mn/m | -$2.4Mn/m | -$1.5Mn/m |
| Retained Earnings | -$4.8Mn/m | -$4.5Mn/m | -$4.2Mn/m | -$4.1Mn/m | -$3.4Mn/m | -$2.9Mn/m | -$2.4Mn/m | -$1.5Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
AFJK Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$346Kn/m | -$157Kn/m | -$75Kn/m | -$43Kn/m | -$96Kn/m | -$202Kn/m | -$224Kn/m | -$195K |
| Investing Cash Flow | -$137Kn/m | -$103Kn/m | -$69K-100.2% | $33.7M | -$450K | -$450K | $30.8M | N/A |
| Financing Cash Flow | $486K-11.2% | $243K-62.4% | $159Kn/m | -$33.6M | $547K | $647K | -$30.6M | N/A |
| Share Buybacks | N/A | N/A | N/A | $34.1M | $0 | $0 | $31.3M | N/A |
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Dividends Paid.
AFJK Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Liabilities-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$4.1M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Aimei Health Technology Co., Ltd AFJK | FY2025 | N/A | $1.1M | N/A | $37.4M | — |
| Rising Dragon Acquisition Corp. RDAC | FY2025 | N/A | $1.6M | N/A | $38.5M | — |
| DT Cloud Star Acquisition Corporation DTSQ | FY2025 | $2.7M | $2.1M | 79.5% | $41.9M | 42/100 |
| Flag Ship Acquisition Corp. FSHP | FY2025 | $2.5M | $1.8M | 73.5% | $40.1M | 47/100 |
| Eureka Acquisition Corp EURK | FY2025 | N/A | $1.4M | N/A | $25.1M | — |
| A SPAC III Acquisition Corp. ASPC | FY2025 | N/A | $1.3M | N/A | $23.8M | — |
Where Aimei Health Technology Co., Ltd Ranks
Frequently Asked Questions
Yes, Aimei Health Technology Co., Ltd (AFJK) reported a net income of $30K over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $1.1M.
Aimei Health Technology Co., Ltd (AFJK) recorded an outflow of $565K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Aimei Health Technology Co., Ltd (AFJK) had $12.1M in total assets as of fiscal year 2025, including both current and long-term assets.
Aimei Health Technology Co., Ltd (AFJK) had a current ratio of 0.00 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
Aimei Health Technology Co., Ltd (AFJK) had a return on assets of 8.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Aimei Health Technology Co., Ltd (AFJK) has no price-to-earnings ratio at the moment: outside the range published as a multiple (on $30K net income, trailing 12 months to September 30, 2026). The market capitalization is $37.4M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Aimei Health Technology Co., Ltd (AFJK) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $37.4M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Aimei Health Technology Co., Ltd (AFJK) has negative shareholder equity of -$4.1M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Aimei Health Technology Co., Ltd (AFJK) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.